Institutional members access full text with Ovid®

LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN WITH SEVERE IMMUNODEFICIENCY

Resino, Salvador PhD*; Alvaro-Meca, Alejandro MSc*; de José, Maria Isabel MD‡; Martin-Fontelos, Pablo MD§; Gutiérrez, Maria Dolores Gurbindo MD†; Léon, Juan Antonio MD∥; Ramos, José Tomás MD¶; Ciria, Luis MD#; Muñoz-Fernández, Maria Ángeles PhD*,1

Pediatric Infectious Disease Journal: April 2006 - Volume 25 - Issue 4 - pp 365-368
doi: 10.1097/01.inf.0000207419.50016.5e
Brief Reports

We conducted a retrospective study to analyze the CD4+ recovery of naive vertically human immunodeficiency virus-infected children with severe immunodeficiency who were followed up during at least 4 years of receiving highly active antiretroviral therapy (HAART). Children with baseline CD4+ of <15% did not reach a mean CD4+ of ≥25% after the 4th year on HAART. We conclude that starting HAART after severe immunosuppression of naive HIV-infected children may not be effective for recovery of normal %CD4+.

From the *Laboratorio de Inmuno-Biología Molecular and †Inmuno-Pediatría, Hospital General Universitario “Gregorio Marañón,” Madrid; ‡Inmuno-Pediatría, Hospital Universitario “La Paz,” Madrid; §Pediatría-Infecciosas, Hospital Universitario “Carlos III,” Madrid; ∥Pediatría-Infecciosas, Hospital Universitario “Virgen de Rocío,” Seville; ¶Inmuno-Pediatría, Hospital Universitario “12 de Octubre,” Madrid; and #Pediatría-Infecciosas; Hospital Universitario “Niño Jesús,” Madrid, Spain

Accepted for publication November 23, 2005.

Supported by Fundación para la Investigación y la Prevención del SIDA en España, FIPSE (grant 12456/03), Fundación para la Investigación Sanitaria (FIS) del Ministerio de Sanidad y Consumo (PI040883, PI052479, PI052472, PI052411), Plan Nacional de Salud (SAF 2003-09209, SAF-2004-06778), Red Temática Cooperativa de investigación en SIDA (RIS G03/173) of FIS, and Red Temática Cooperativa de investigación en Genética (RIG C03/07). Dr Resino received a staff research grant from FIS (CP04/00090).

E-mail sresino.hgugm@salud.madrid.org. Reprints not available.

© 2006 Lippincott Williams & Wilkins, Inc.